Kisspeptin-10: Technical-Scientific Review and Perspectives in Oncology

Important Summary

Kisspeptin-10 is a biologically active peptide derived from the larger kisspeptin protein, encoded by the KISS1 gene. It acts through the G protein-coupled receptor KISS1R, also known as GPR54. Initially identified as a metastasis suppressor, the KISS1/KISS1R axis has gained relevance in experimental oncology. However, its primary recognized physiological role is the regulation of the reproductive axis, stimulating GnRH release.

It is important to emphasize that peptides are not medications. A peptide is a biomolecule formed by the union of two or more amino acids through specific chemical bonds called peptide bonds.

Why Do Peptides Act in Healing Processes?
Unlike synthetic drugs that often “force” a chemical reaction in the body, peptides function as biological messengers. They possess specific “keys” that bind to cellular receptors, sending instructions to:

1. Cellular Signaling: Indicate when the body should repair tissue.
2. Hormonal Regulation: Help balance metabolic processes.
3. Immune Response: Naturally modulate the body’s defense mechanisms.

In summary: A peptide is a “biological instruction” in molecular form. It is not the drug itself, but the code that instructs the body on how to restore homeostasis (healthy balance).

1. Structure and Molecular Characteristics

Kisspeptin-10 is a 10-amino acid fragment derived from kisspeptin-54 (metastin). It is considered the smallest biologically active fragment capable of activating the KISS1R receptor.

Key characteristics:

• Short peptide structure (10 amino acids)
• High affinity for the KISS1R receptor
• Activation of intracellular signaling pathways via Gq/11 protein
• Stimulation of the PLC → IP3 → intracellular Ca²⁺ cascade

2. Main Physiological Function

The most established role of Kisspeptin-10 is in:

• Regulation of puberty
• Control of the hypothalamic-pituitary-gonadal axis
• Stimulation of GnRH secretion

Its current clinical applications are mainly focused on:

• Infertility research
• Evaluation of hypothalamic function

3. Mechanism of Action in Oncology

Oncological interest emerged when the KISS1 gene was identified as a metastasis suppressor gene in melanoma.

🧬 3.1 Metastasis Suppression
Preclinical studies demonstrate that Kisspeptin-10 may:

• Reduce tumor cell migration
• Decrease extracellular invasion
• Modulate matrix metalloproteinases (MMPs)
• Alter MAPK and ERK signaling pathways
• Reduce angiogenesis in some models

Experimentally studied tumors:

• Melanoma
• Breast cancer
• Pancreatic cancer
• Gastric cancer

Important:
Its effect is predominantly anti-metastatic, not directly cytotoxic.

4. Does It Kill Tumor Cells?

Not directly.

Unlike cytolytic or pro-apoptotic peptides, Kisspeptin-10:

• Does not cause membrane lysis
• Does not induce massive apoptosis on its own
• Acts by modulating cellular behavior rather than destroying primary tumors

5. Clinical Evidence

To date:

• There are no Phase III clinical trials demonstrating antitumor efficacy.
• It is not approved as an oncology drug by the FDA, EMA, or other major agencies.
• Most evidence remains preclinical (in vitro and animal models).

6. Is It the Best Treatment for Cancer?

Objective scientific answer: No.

Reasons:

1. Cancer is a heterogeneous group of diseases.
2. Kisspeptin-10 does not show robust cytotoxic activity.
3. It has not demonstrated tumor regression as a standalone treatment in humans.
4. Its role is regulatory and experimentally anti-metastatic.

It may, in the future, be part of combined therapeutic strategies, but:

It does not replace surgery, chemotherapy, radiotherapy, immunotherapy, or targeted therapies. Its use and application are still in scientific and clinical research stages.

7. When and How Could It Be Widely Used?

For broad use in oncology, several steps would be required:

7.1 Structured Clinical Trials

• Phase I: Safety
• Phase II: Preliminary efficacy
• Phase III: Comparison with standard of care

7.2 Definition of Specific Indications

Potential future roles:

• Metastasis modulator
• Post-surgical adjuvant therapy
• Component of combination therapy

7.3 Pharmaceutical Development

• Increased plasma stability
• Targeted delivery systems
• Long-acting formulations

7.4 Regulatory Approval

Submission to FDA (USA), EMA (Europe), ANVISA (Brazil), and other global agencies.

Currently, this process is not advanced for oncology, and there is no scientific validation for such use.

8. Safety

In clinical studies related to fertility, Kisspeptin-10 has shown:

• A relatively favorable safety profile
• Few significant adverse effects
• Short half-life

However, long-term oncological safety remains undefined.

9. Current Scientific Perspective

Kisspeptin-10 should be classified as:

A regulatory peptide with potential to modulate tumor progression, still under preclinical investigation.

It is not:

• A standard therapy
• A proven treatment
• A cure for cancer

However, it represents a promising field in metastasis biology, with extensive ongoing scientific research.

Final Conclusion

Kisspeptin-10:

✔️ Has a well-established biological role in the reproductive axis
✔️ Demonstrates anti-metastatic potential in experimental models and is considered promising in oncology research

❌ Is not the best treatment for cancer
❌ Has not demonstrated tumor cure
❌ Does not have widely validated oncological approval

Its future will depend on:

• Investment in large-scale clinical trials
• Better understanding of KISS1/KISS1R pathways
• Integration with combination therapies and advanced scientific research